# Zilia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zilia

- Industry: Medical Devices & Equipment
- Headquarters: Quebec, Canada
- Website: www.ziliahealth.com/
- Total disclosed funding: $3.2M
- Latest round: Seed (Aug 11, 2021)
- Investors on record: 2

## About

Based in Canada, Zilia Inc. operates as a provider of innovative technology for the assessment of ocular biomarkers, focusing on its flagship device designed to enhance disease diagnosis and treatment.Zilia Inc. specializes in the development and commercialization of technology aimed at assessing biomarkers in the eye. Founded in 2012 in Quebec City, Canada, the company has completed a total of 3 funding deals, with the latest funding round being a Seed round in May 2025, raising CAD 4.000 mn led by Anges Quebec and supported by Investment Quebec. The company was co-founded by Dominic Sauvageau and Patrick Sauvageau, with Patrick currently serving as CEO.Zilia Inc. is focused on the development and commercialization of pioneering technology designed to assess biomarkers in the eye, with a primary emphasis on its flagship product, the Zilia Ocular retinal camera. This innovative device non-invasively measures blood oxygen saturation levels in the eye, which can provide critical insights into various ocular, neurological, and systemic diseases. The Zilia Ocular camera aims to address significant health challenges, particularly in the prevention, diagnosis, and treatment of leading causes of vision loss such as glaucoma, diabetic retinopathy, and age-related macular degeneration. The technology utilizes advanced imaging techniques, spectrometry, and artificial intelligence, making it a comprehensive solution for healthcare professionals. Zilia targets clinical settings within various geographical markets, including North America and Europe, where healthcare providers seek effective tools for eye care and disease management.Zilia Inc. generates revenue primarily through the sale of its Zilia Ocular retinal cameras and associated services to healthcare providers and diagnostic centers. The company's business model encompasses direct sales to end-users, facilitating a seamless transaction process for healthcare professionals seeking to enhance their diagnostic capabilities. Revenue generation occurs through one-time equipment purchases, as well as potential recurring revenue from service contracts or software updates. While specific pricing structures for the Zilia Ocular system are not disclosed, the business operates on a model that likely includes customized pricing plans tailored to the needs of medical facilities. Through this approach, Zilia positions itself as a key player in the ocular health technology sector, providing vital tools that align with the evolving needs of its client base.In May 2025, Zilia Inc. raised CAD 4.000 mn from new investor Linearis and other unspecified investors. The company will utilize this funding to support its commercialization plans and regulatory preparation. Zilia is focused on launching new products, specifically enhancements to its existing technology, and aims to expand its presence in North America and Europe by targeting additional healthcare markets over the next few years.

## Funding rounds

- Seed, Aug 11, 2021, $3.2M — Investment Quebec, Anges Quebec

## Investors

- Investment Quebec (https://capitalatlas.ai/funds/investment-quebec) — Seed
- Anges Quebec — Seed